Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

Conclusions. VR DLBCL is a rare disease, which can occur as primary, concurrent with systemic, or in relapsed disease. OS over the decades has significantly improved. In PVRL, no late CNS relapses were observed, while late intraocular relapses can occur. A combined approach with intraocular + systemic HD-MTX based treatment at diagnosis was associated with a higher FFS and CNS-relapse free survival in PVRL and is recommended in bilateral involvement, even though no differences in OS were observed. Treatment consolidation with ASCT can be considered in cases with concurrent systemic disease. Further studies are needed to confirm these results and to better define the role of new drugs in treatment of this uncommon malignancy.DisclosuresWitzig: Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Castellino, A., Pulido, J., Johnston, P., Ristow, K. M., Bennani, N. N., Inwards, D. J., Macon, W. R., Micallef, I. N., King, R. L., Salomao, D., Witzig, T. E., Habermann, T. M., Nowakowski, G. Tags: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Outcomes Of Lymphoma In The Elderly Source Type: research